Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine
China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...
Biotech
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...
Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences...
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...
MaxHealth Biotechnology Completes Series B+ Financing Round
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine
China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...
Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...
Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...
China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine
Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline
China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...
Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...